@onclive.bsky.social📈 The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC. @ascocancer.bsky.social #ASCO26 #lcsm #oncology
More insights ➡️: www.onclive.com/view/tegaviv...
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: What Does It All Mean? What You Need To Know About AI presented by Anita Grigoriadis. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.social📅 Register now!
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
@lungcancereurope.bsky.socialCould MRI find #lungcancer spread that CT misses?
A 🆕 collagen-targeted contrast agent detected lung tumours as small as 0.6 mm & adrenal metastases as small as 0.1 mm in preclinical models of LKB1-mutant lung adenocarcinoma.
Could it do the same in people?
@lungcancereurope.bsky.socialWhat can have the biggest impact on quality of life after a #lungcancer diagnosis?
Fatigue, breathlessness, work, finances & loss of independence are just some of the issues people may face.
Please help us reach people living with lung cancer & caregivers:
es.surveymonkey.com/r/LungCancer... #LCSM
@onclive.bsky.social📺 In this episode of The Moonlight Shift, Jyoti Malhotra, MD, discusses first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to @yalecancer.bsky.social. #lcsm #oncology
Watch now ➡️: www.onclive.com/view/first-i...
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: Where now? The Future of Interventional Bronchoscopy presented by Ricky Thakrar. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: Physician-led, point of care genomic testing in the lung cancer pathway presented by Matthew Evison. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@lungcancereurope.bsky.socialThis week, Germany announced a new network to help deliver #lungcancer screening in practice.
The network links 25 radiology screening sites with specialist second-reading centres in Heidelberg, supporting consistent reporting and follow-up.
Screening is about delivery as well as policy. #LCSM
@alkpositiveuk.bsky.socialCould alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
@onclive.bsky.social🗞️Just in: The FDA has granted fast track designation to the PD-1 x VEGF bispecific antibody cesalatamig for NSCLC after disease progression following concurrent or sequential PD-(L)1–targeted immunotherapy and platinum-based chemotherapy #lcsm #oncology www.onclive.com/view/fda-gra...
@eaonc.bsky.socialThe EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: How Are We Doing? Results of the BTS Pilot Audit presented by Emma O’Dowd. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@onclive.bsky.socialOn this Two Onc Docs episode, Samantha A. Armstrong, MD, and @drkarinetawagi.bsky.social host a board-focused review of mNSCLC diagnosis and management. @uofillinois.bsky.social #lcsm #oncology
Listen to the episode on our site or your favorite podcast platforms! www.onclive.com/view/non-sma...
@onclive.bsky.social🗞️Just in: The FDA has approved a labeling update that reduces the post-infusion monitoring period to 6 to 8 hours following the first two doses of tarlatamab in patients with ES-SCLC #lcsm #oncology
www.onclive.com/view/fda-red...
@lungcancereurope.bsky.socialBetter #lungcancer diagnosis needs collaboration across the whole pathway.
At #WCLC26, our VP presented collaborative work with Lung Cancer Policy Network work drawing on evidence, 12 expert interviews and contributions from multidisciplinary members. #LCSM
@alkpositiveuk.bsky.socialThe 5th ALK Positive Lung Cancer UK National Conference is coming up on 25–27 September.
Expert speakers will cover clinical trials, ALK research, survivorship, side effects, pharmacy advice and more, with plenty of time for questions and peer support. #LCSM
@alkpositiveuk.bsky.socialOur 2025 Impact Report looks back at everything our ALK+ #lungcancer community helped make possible, from our biggest national conference yet and growing regional meet-ups to new support, trusted information and stronger advocacy for people with ALK+.
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: BTOG 2026 BTOG 2026 Young Researcher of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: BTOG 2026 Doctor of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer